Physician profile
Chakun Mcdaniel
NPI 1316416555
$10,603.81
in general payments reported to CMS, 2019-2025
29 companies · $3,153 in 2025
The $3,153 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,164 · 2022: $2,456 · 2023: $977 · 2024: $1,853 · 2025: $3,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,844 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,844.42 |
| Education | $138.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,615.50 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,409.16 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,265.74 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $1,054.05 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Supernus Pharmaceuticals, INC. | $985.56 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $503.88 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $479.88 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $471.64 | 2022-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $377.48 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $362.72 | 2021-2025 | Rexulti |
| Neos Therapeutics, LP | $301.43 | 2021-2025 | Adzenys Xr-Odt |
| Tris Pharma INC | $246.66 | 2022-2024 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $232.14 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $175.33 | 2021-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Eisai INC. | $160.08 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $151.09 | 2021-2022 | |
| Almatica Pharma LLC | $147.65 | 2022-2025 | Loreev Xr |
| Corium, LLC | $127.89 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $125.00 | 2022 | |
| Indivior INC. | $81.93 | 2022-2025 | Sublocade |
| Avanir Pharmaceuticals, INC. | $80.54 | 2021 | |
| Noven Therapeutics, LLC | $55.96 | 2022-2025 | Xelstrym, Secuado |
| Merck Sharp & Dohme LLC | $45.48 | 2022 | |
| Adlon Therapeutics L.P. | $43.91 | 2021 | |
| Idorsia Pharmaceuticals US INC | $27.51 | 2022 | |
| Aytu Biopharma, INC. | $24.07 | 2025 | |
| Luye Pharma (USA) LTD. | $21.40 | 2025 | Erzofri Extended-Release |
| Bausch Health US, LLC | $17.33 | 2025 | Aplenzin, Wellbutrin |
| Abbott Laboratories | $12.80 | 2023 | Proclaim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chakun Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.